Chemistry:Tavolimab
Please use PROD only on articles. It is proposed that this article be deleted because of the following concern:
If you can address this concern by improving, copyediting, sourcing, renaming, or merging the page, please edit this page and do so. You may remove this message if you improve the article or otherwise object to deletion for any reason. Although not required, you are encouraged to explain why you object to the deletion, either in your edit summary or on the talk page. If this template is removed, do not replace it. This message has remained in place for seven days, so the article may be deleted without further notice. Nominator: Please consider notifying the author/project: {{subst:proposed deletion notify|Chemistry:Tavolimab|concern=too early for an article, nothing on PubMed}} ~~~~Timestamp: 20181017012423 01:24, 17 October 2018 (UTC) Administrators: delete |
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Chimeric/Humanized hybrid (mouse/human) |
| Target | CD134 |
| Clinical data | |
| Other names | MEDI0562 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6508H10026N1730O2032S42 |
| Molar mass | 146.4 g/mol g·mol−1 |
Tavolimab (MEDI0562, formerly tavolixizumab) (INN[1]) is a chimeric/humanized monoclonal antibody designed for the treatment of cancer.
This drug is being developed by MedImmune.[2]
References
- ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information 30 (2). http://www.who.int/medicines/publications/druginformation/innlists/PL115.pdf.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Tavolimab, American Medical Association.
 |
